Stockreport

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE [Yahoo! Finance]

Astria Therapeutics, Inc.  (ATXS) 
PDF -- 67% Attack-Free Rate Over 6 Months in Cohorts 2 and 3 -- -- Favorable Safety and Well-Tolerated Profile -- -- Phase 3 Initiation on Track for Q1 2025 -- BOSTON [Read more]